Dateline City:
WHITEHOUSE STATION N.J.
WHITEHOUSE STATION N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that its New Drug Application for an investigational,
tablet formulation of the company's antifungal agent, NOXAFIL
(posaconazole), has been accepted for review by the U.S. Food and Drug
Administration (FDA).
Language:
English
Contact HTML:
MerckMedia:Pam Eisele, (908) 423-5042Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more